Targeting regulatory T cells.
Cancers express tumor-associated antigens that should elicit immune response to antagonize the tumor growth, but spontaneous immune rejection of established cancer is rare, suggesting an immunosuppressive environment hindering host antitumor immunity. Among the specific and active tumor-mediated mechanisms, CD4(+)CD25(high) T regulatory cells (Treg) are important mediators of active immune evasion in cancer. In this review, we will discuss Treg subpopulations and the mechanisms of their suppressive functions. Treg depletion improves endogenous antitumor immunity and the efficacy of active immunotherapy in animal models for cancer, suggesting that inhibiting Treg function could also improve the limited successes of human cancer immunotherapy. We will also discuss specific strategies for devising effective cancer immunotherapy targeting Treg.
Université de Lyon, F-69000, Lyon, France. christine.caux@lyon.unicancer.fr
Christine
C
Ménétrier-Caux
Tyler
T
Curiel
Julien
J
Faget
Manuarii
M
Manuel
Christophe
C
Caux
Weiping
W
Zou
D000818:Animals; D002450:Cell Communication / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D008212:Lymphocyte Depletion / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D019139:Tumor Escape; D059016:Tumor Microenvironment